@article{10607,
  keywords = {*Breast Neoplasms/chemically induced/epidemiology, Case-Control Studies, Estrogen Replacement Therapy/adverse effects, Estrogens/adverse effects, Female, Humans, Menopause, Progesterone/adverse effects, Progestins/therapeutic use, Risk Factors},
  author = {H. Abenhaim and S. Suissa and L. Azoulay and A. Spence and N. Czuzoj-Shulman and T. Tulandi},
  title = {Menopausal Hormone Therapy Formulation and Breast Cancer Risk},
  year = {2022},
  journal = {Obstet Gynecol},
  volume = {139},
  edition = {2022/06/09},
  number = {6},
  pages = {1103-1110},
  isbn = {0029-7844},
  doi = {10.1097/aog.0000000000004723},
  note = {1873-233x
Abenhaim, Haim A
Suissa, Samy
Azoulay, Laurent
Spence, Andrea R
Czuzoj-Shulman, Nicholas
Tulandi, Togas
Journal Article
United States
Obstet Gynecol. 2022 Jun 1;139(6):1103-1110. doi: 10.1097/AOG.0000000000004723. Epub 2022 May 3.},
  language = {eng},
}